Chronic Myeloid Leukemia in a Patient Receiving Tofacitinib: A Case Report and Literature Review

BACKGROUND: Tofacitinib is a new oral Janus kinase inhibitor that has shown promising clinical benefit in various rheumatologic diseases. However, many concerns related to the development of malignancies have been reported with its use. CASE PRESENTATION: A 43-year-old female patient received tofaci...

Descripción completa

Detalles Bibliográficos
Autores principales: Medawar, Georgio, Chahrouri, Joseph, Said, Rabih
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6556791/
https://www.ncbi.nlm.nih.gov/pubmed/31263618
http://dx.doi.org/10.1155/2019/2814504

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6556791/
https://www.ncbi.nlm.nih.gov/pubmed/31263618
http://dx.doi.org/10.1155/2019/2814504

Ejemplares similares